Assembly Biosciences, Inc. (ASMB) stock
ASMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/309% below fair value
$22.39−0.11 (-0.49%)
Close on Nov 18, 2026Market cap $455.87MP/E –Yield –
Assembly Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Assembly Biosciences's revenue for the twelve months ending Jun 30, 2026 was $74.85M, up 125.1% year over year. For fiscal 2025 it was $72.30M, up 153.5% from the year before. The highest annual figure on record is $79.11M in fiscal 2020.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.30M | +153.5% |
| FY2024 | Dec 31, 2024 | $28.52M | +298.2% |
| FY2023 | Dec 31, 2023 | $7.16M | – |
| FY2022 | Dec 31, 2022 | $0 | -100.0% |
| FY2021 | Dec 31, 2021 | $6.25M | -92.1% |
| FY2020 | Dec 31, 2020 | $79.11M | +395.6% |
| FY2019 | Dec 31, 2019 | $15.96M | +7.8% |
| FY2018 | Dec 31, 2018 | $14.80M | +64.1% |
| FY2017 | Dec 31, 2017 | $9.02M | – |
| FY2016 | Dec 31, 2016 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.37M | +38.9% |
| Q1 FY2026 | Mar 31, 2026 | $8.21M | -12.8% |
| Q4 FY2025 | Dec 31, 2025 | $42.47M | +477.3% |
| Q3 FY2025 | Sep 30, 2025 | $10.79M | +57.6% |
| Q2 FY2025 | Jun 30, 2025 | $9.63M | +12.8% |
| Q1 FY2025 | Mar 31, 2025 | $9.42M | +62.8% |
| Q4 FY2024 | Dec 31, 2024 | $7.36M | +2.7% |
| Q3 FY2024 | Sep 30, 2024 | $6.85M | – |
| Q2 FY2024 | Jun 30, 2024 | $8.53M | – |
| Q1 FY2024 | Mar 31, 2024 | $5.79M | – |
| Q4 FY2023 | Dec 31, 2023 | $7.16M | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $0 | -100.0% |
| Q1 FY2023 | Mar 31, 2023 | $0 | -100.0% |
| Q4 FY2021 | Dec 31, 2021 | $0 | -100.0% |
| Q3 FY2021 | Sep 30, 2021 | $6.25M | +53.2% |
| Q4 FY2020 | Dec 31, 2020 | $1.04M | -78.2% |
| Q3 FY2020 | Sep 30, 2020 | $34.61M | +718.0% |
| Q2 FY2020 | Jun 30, 2020 | $39.38M | +1178.4% |
| Q1 FY2020 | Mar 31, 2020 | $4.08M | +5.0% |
| Q4 FY2019 | Dec 31, 2019 | $4.77M | +27.6% |
| Q3 FY2019 | Sep 30, 2019 | $4.23M | -1.3% |
| Q2 FY2019 | Jun 30, 2019 | $3.08M | -4.3% |
| Q1 FY2019 | Mar 31, 2019 | $3.89M | +9.0% |
| Q4 FY2018 | Dec 31, 2018 | $3.74M | +12.7% |
| Q3 FY2018 | Sep 30, 2018 | $4.29M | +61.1% |
| Q2 FY2018 | Jun 30, 2018 | $3.22M | +36.4% |
| Q1 FY2018 | Mar 31, 2018 | $3.57M | +421.2% |
| Q4 FY2017 | Dec 31, 2017 | $3.32M | – |
| Q3 FY2017 | Sep 30, 2017 | $2.66M | – |
| Q2 FY2017 | Jun 30, 2017 | $2.36M | – |
| Q1 FY2017 | Mar 31, 2017 | $684.00K | – |
See a number that looks wrong?